← Eichor
Study identifier: NCT06912763 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Condition: Fibrosis Syndrome · Lymphedema · Head &Amp; Neck Cancer  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants250
Who can joinFemale, N/A to no upper limit
Healthy volunteersNo

About this study

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

This description comes directly from the study's public registry record.

Talk to the study team

Clifton Fuller, MD  ·  (832) 817-8568  ·  cdfuller@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06912763